Press releases
- Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
- Precigen Reports First Quarter 2024 Financial Results and Business Updates
- Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
- Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
- Actym Therapeutics Appoints Thomas Smart as CEO
- Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
- Precigen Reports Full Year 2023 Financial Results and Business Updates
- Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
- Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
More ▼
Key statistics
On Friday, Precigen Inc (I5X:DUS) closed at 1.23, -25.78% below its 52-week high of 1.66, set on Sep 04, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.19 |
---|---|
High | 1.27 |
Low | 1.19 |
Bid | 1.28 |
Offer | 1.33 |
Previous close | 1.21 |
Average volume | 0.00 |
---|---|
Shares outstanding | 252.42m |
Free float | 223.44m |
P/E (TTM) | -- |
Market cap | 353.39m USD |
EPS (TTM) | -0.3896 USD |
Data delayed at least 15 minutes, as of May 31 2024 18:30 BST.
More ▼